Atara Biotherapeutics, Inc. (ATRA): restructuring charge — Atara Biotherapeutics reduces workforce by ~30% to retain ~23 employees

Atara Biotherapeutics, Inc.

Approximately 30% workforce reduction, retaining ~23 employees; expected completion by August 2025.
Expected severance and related costs of $1.4 million in one-time cash charges.
Additional details to be provided in the Q2 2025 10-Q filing.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Atara Biotherapeutics, Inc. announced a restructuring with charges of approximately $1.4 million (approximately 30% of its current employees).

Type: restructuring
Charge: approximately $1.4 million
Headcount: approximately 30% of its current employees

Exact text from the filing

to executing on the Company’s strategic priorities. The Company expects to complete the workforce reduction by August 2025. The Company expects to recognize approximately $1.4 million for severance and related benefits for employees laid off under the reduction in force. These charges are primarily one-time termination benefits and are primarily cash charges.

View on SEC.gov

13 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Atara Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-069198

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.